C4 glomerulopathy Medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{C4 glomerulopathy}} {{CMG}}; {{APM}}; {{AE}} {{OO}} ==Overview== ==Medical Therapy== ==References== {{Reflist|2}} {{WH}}{{WS}}")
 
 
(3 intermediate revisions by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
The mainstay of treatment for C4 glomerulopathy is antihypertensive and lipid-lowering drugs.


==Medical Therapy==
==Medical Therapy==
Pharmacologic medical therapies for C4 glomerulopathy include<ref name="AppelCook2005">{{cite journal|last1=Appel|first1=Gerald B.|last2=Cook|first2=H. Terence|last3=Hageman|first3=Gregory|last4=Jennette|first4=J. Charles|last5=Kashgarian|first5=Michael|last6=Kirschfink|first6=Michael|last7=Lambris|first7=John D.|last8=Lanning|first8=Lynne|last9=Lutz|first9=Hans U.|last10=Meri|first10=Seppo|last11=Rose|first11=Noel R.|last12=Salant|first12=David J.|last13=Sethi|first13=Sanjeev|last14=Smith|first14=Richard J.H.|last15=Smoyer|first15=William|last16=Tully|first16=Hope F.|last17=Tully|first17=Sean P.|last18=Walker|first18=Patrick|last19=Welsh|first19=Michael|last20=Würzner|first20=Reinhard|last21=Zipfel|first21=Peter F.|title=Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update|journal=Journal of the American Society of Nephrology|volume=16|issue=5|year=2005|pages=1392–1403|issn=1046-6673|doi=10.1681/ASN.2005010078}}</ref><ref name="AliSchlanger2016">{{cite journal|last1=Ali|first1=Arshad|last2=Schlanger|first2=Lynn|last3=Nasr|first3=Samih H.|last4=Sethi|first4=Sanjeev|last5=Gorbatkin|first5=Steven M.|title=Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure|journal=American Journal of Kidney Diseases|volume=67|issue=3|year=2016|pages=479–482|issn=02726386|doi=10.1053/j.ajkd.2015.10.020}}</ref>:
*Lipid-lowering drugs
*Antihypertensive drugs
**ACE-inhibitors
**Angiotensin-II inhibitors
*Immunosuppressive therapy


==References==
==References==

Latest revision as of 17:05, 8 August 2020

C4 glomerulopathy Microchapters

Complement Mediated Glomerular Disorders Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating C4 glomerulopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

C4 glomerulopathy Medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of C4 glomerulopathy Medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on C4 glomerulopathy Medical therapy

CDC on C4 glomerulopathy Medical therapy

C4 glomerulopathy Medical therapy in the news

Blogs on C4 glomerulopathy Medical therapy

Directions to Hospitals Treating C4 glomerulopathy

Risk calculators and risk factors for C4 glomerulopathy Medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

The mainstay of treatment for C4 glomerulopathy is antihypertensive and lipid-lowering drugs.

Medical Therapy

Pharmacologic medical therapies for C4 glomerulopathy include[1][2]:

  • Lipid-lowering drugs
  • Antihypertensive drugs
    • ACE-inhibitors
    • Angiotensin-II inhibitors
  • Immunosuppressive therapy

References

  1. Appel, Gerald B.; Cook, H. Terence; Hageman, Gregory; Jennette, J. Charles; Kashgarian, Michael; Kirschfink, Michael; Lambris, John D.; Lanning, Lynne; Lutz, Hans U.; Meri, Seppo; Rose, Noel R.; Salant, David J.; Sethi, Sanjeev; Smith, Richard J.H.; Smoyer, William; Tully, Hope F.; Tully, Sean P.; Walker, Patrick; Welsh, Michael; Würzner, Reinhard; Zipfel, Peter F. (2005). "Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update". Journal of the American Society of Nephrology. 16 (5): 1392–1403. doi:10.1681/ASN.2005010078. ISSN 1046-6673.
  2. Ali, Arshad; Schlanger, Lynn; Nasr, Samih H.; Sethi, Sanjeev; Gorbatkin, Steven M. (2016). "Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure". American Journal of Kidney Diseases. 67 (3): 479–482. doi:10.1053/j.ajkd.2015.10.020. ISSN 0272-6386.

Template:WHTemplate:WS